Oncolytics Biotech Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights ® Pancreatic Cancer Program Reported a 69% ORR and confirmed complete response in phase 1/2 GOBLET trial's pancreatic cancer cohort Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients Phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer on track for ...

Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Jon Patton - Director, IR & Communication Matt Coffey - CEO Tom Heineman - CMO Andrew de Guttadauro - Global Head, Business Development Kirk Look - CFO Conference Call Participants John Newman - Canaccord Operator Good morning, and welcome to Oncolytics Biotech's Third Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session ...

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. September 30, 2022 and 2021 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | | | September 30, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2022 | | 2021 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 32,362,063 | $ | 41,262,044 | | Other receivables (note 8) | | 496,855 | | 866,055 | | Prepaid expenses | | 5,346,353 ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2022 Results Conference Call August 11, 2022 8:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Matthew Coffey - President and Chief Executive Officer Kirk Look - Chief Financial Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - President Conference Call Participants Jason Kolber - HC Wainwright Operator Good afternoon, and welcome to Oncolytics BiotechÂ's Second Quarter 2022 Conference Call. All partic ...

(in Canadian dollars, except share amounts) | | | June 30, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2022 | | 2021 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 33,689,255 | $ | 41,262,044 | | Other receivables (note 8) | | 355,606 | | 866,055 | | Prepaid expenses | | 5,362,596 | | 2,775,800 | | Total current assets | | 39,407,457 | | 44,903,899 | | Property and equipment | | 392,116 | | 392,041 | | Right-of-use assets | | 439,754 | | 584,251 ...

Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Corporate Participants Jon Patton - Director, Investor Relations and Communications Matthew Coffey - President and Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Jason Kolbert - HC Wainwright Operator Good aft ...

Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q4 2021 Earnings Conference Call March 3, 2022 5:00 PM ET Company Participants Jon Patton - Director, IR & Communication Matthew Coffey - President, CEO & Director Thomas Heineman - Chief Medical Officer Kirk Look - CFO Andrew de Guttadauro - Global Head, Business Development & President, Oncolytics Biotech (U.S.) Inc Conference Call Participants Operator Good afternoon, and welcome to Oncolytics Biotech's Fourth Quarter 2021 Conference Call. [Operator Instructions] Pl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2021 Earnings Conference Call November 5, 2021 8:00 AM ET Company Participants Jon Patton - Director of Investor Relations & Communications Matt Coffey - President, Chief Executive Officer & Director Tom Heineman - Global Head of Clinical Development & Operations Andrew de Guttadauro - Global Head of Business Development Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Good mo ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2021 Results Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants Jon Patton - Director, IR and Communication Matt Coffey - President and CEO Tom Heineman - Global Head, Clinical Development and Operations Andrew de Guttadauro - Global Head, Business Development Kirk Look - CFO Conference Call Participants John Newman - Canaccord Patrick Trucchio - H.C. Wainwright Operator Good morning. And welcome to Oncolytics BiotechÂ's Second Quarter 2021 Confe ...